David J Wullimann|David J. Wullimann

David J Wullimann|David J. Wullimann

Karolinska Institute - Stockholm / Sweden
Medical and Health Sciences / Immunology
AD Scientific Index ID: 1412191
Karolinska Institutet
person_outline David J Wullimann|David J. Wullimann's MOST POPULAR ARTICLES
1-) Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19T Sekine, A Perez-Potti, O Rivera-Ballesteros, K Strålin, JB Gorin, ...Cell 183 (1), 158-168. e14, 202015122020
2-) Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trialP Bergman, O Blennow, L Hansson, S Mielke, P Nowak, P Chen, ...EBioMedicine 74, 103705, 2021912021
3-) Cytotoxic T-cells mediate exercise-induced reductions in tumor growthH Rundqvist, P Veliça, L Barbieri, PA Gameiro, D Bargiela, M Gojkovic, ...Elife 9, e59996, 2020592020
4-) Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccinationY Gao, C Cai, D Wullimann, J Niessl, O Rivera-Ballesteros, P Chen, ...Immunity 55 (9), 1732-1746. e5, 2022562022
5-) NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individualsA Cuapio, C Boulouis, I Filipovic, D Wullimann, T Kammann, T Parrot, ...Molecular Medicine 28 (1), 20, 2022272022